RxDoctor Payments Data

Rajiv Pathak, MD

Internal Medicine · Dana Point, CANPI 1265528111

Payments from drug & device makers

$2,760in general payments, 2019–2025

Across 60 payments — averaging $45.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$566
  • Amgen$279
  • Amarin Pharma, Inc.$111
  • Gilead$100
  • Lilly USA, LLC$48
  • plus $106 from 4 others

What the payments were for

  • Food & beverage$2,754100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)23$1,550
Novo Nordisk21$566
Amgen3$279
Amarin Pharma, Inc.2$111
Gilead1$100
Lilly USA, LLC3$48
AbbVie3$42
GSK2$30
Abbott1$19
Astellas Pharma US Inc1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,760 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$204,391
Medicare patients
326
Services billed
2,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$208,952
JanuviaSitagliptin Phosphate126$170,553
FarxigaDapagliflozin Propanediol125$168,087
EliquisApixaban89$85,431
JardianceEmpagliflozin46$74,895
RybelsusSemaglutide21$48,309
JanumetSitagliptin Phos/Metformin Hcl27$40,027
ProliaDenosumab20$34,248
TrulicityDulaglutide17$32,578
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$23,031
KerendiaFinerenone11$18,271
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$17,574
LinzessLinaclotide13$14,828
XareltoRivaroxaban14$14,799
TradjentaLinagliptin11$13,955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$566$257,261119 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,550$191,118149 claims
AmgenProlia$279$34,24820 claims
Lilly USA, LLCTrulicity$48$32,57817 claims
AbbVieLinzess$42$14,82813 claims
GSKShingrix$30$2,68313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Dana Point

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →